# reload+after+2024-01-20 10:43:08.820047
address1§640 Lee Road
address2§Suite 200
city§Wayne
state§PA
zip§19087
country§United States
phone§484 324 7933
website§https://www.aclaristx.com
industry§Diagnostics & Research
sector§Healthcare
longBusinessSummary§Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment offers laboratory services. The company develops Zunsemetinib, an MK2 inhibitor for the treatment of moderate to severe rheumatoid and Psoriatic arthritis, and Hidradenitis suppurativa; and ATI-1777, a soft JAK 1/3 inhibitor for the treatment of moderate to severe atopic dermatitis. It develops ATI-2138, an ITK/TXK/JAK3 inhibitor as a potential treatment for T cell-mediated autoimmune diseases; Gut-Biased Program for inflammatory bowel disease; and ATI-2231, an oral MK2 inhibitor for the treatment of pancreatic and metastatic breast cancer. Aclaris Therapeutics, Inc. was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.
fullTimeEmployees§100
companyOfficers§[{'maxAge': 1, 'name': 'Dr. Neal S. Walker D.O.', 'age': 53, 'title': 'Co-Founder & Chairman', 'yearBorn': 1970, 'fiscalYear': 2022, 'totalPay': 955688, 'exercisedValue': 0, 'unexercisedValue': 5271181}, {'maxAge': 1, 'name': 'Dr. Douglas J. Manion Frcp(C), M.D.', 'age': 61, 'title': 'CEO, President & Director', 'yearBorn': 1962, 'fiscalYear': 2022, 'totalPay': 572160, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Joseph  Monahan Ph.D.', 'age': 67, 'title': 'Chief Scientific Officer', 'yearBorn': 1956, 'fiscalYear': 2022, 'totalPay': 600021, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Gail  Cawkwell M.D., Ph.D.', 'age': 60, 'title': 'Chief Medical Officer', 'yearBorn': 1963, 'fiscalYear': 2022, 'totalPay': 371166, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Kevin  Balthaser', 'age': 36, 'title': 'Chief Financial Officer', 'yearBorn': 1987, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Robert A. Doody Jr.', 'title': 'Senior Vice President of Investor Relations', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Matthew  Rothman J.D.', 'title': 'General Counsel & Corporate Secretary', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Jill  Conwell', 'title': 'Chief People Officer', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Gary A. DeCrescenzo', 'title': 'Senior Vice President of Pharmaceutical Research & Development', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Jon  Jacobsen Ph.D.', 'title': 'Senior Vice President of Chemistry', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
auditRisk§8
boardRisk§8
compensationRisk§9
shareHolderRightsRisk§8
overallRisk§8
governanceEpochDate§1704067200
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§4
payoutRatio§0.0
beta§0.175
priceToSalesTrailing12Months§3.50347
currency§USD
dateShortInterest§1702598400
forwardEps§-1.23
pegRatio§-0.01
exchange§NMS
quoteType§EQUITY
shortName§Aclaris Therapeutics, Inc.
longName§Aclaris Therapeutics, Inc.
firstTradeDateEpochUtc§1444138200
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§7ce3d940-7ceb-3e8d-9e47-4f01c59483ef
gmtOffSetMilliseconds§-18000000
targetHighPrice§9.0
targetLowPrice§1.0
targetMeanPrice§3.79
targetMedianPrice§2.0
recommendationMean§2.1
recommendationKey§buy
numberOfAnalystOpinions§7
quickRatio§3.785
grossMargins§0.0
ebitdaMargins§0.0
trailingPegRatio§None
